TABLE 2.

Current commercially available inhaled antibiotic formulations

Antibiotic (trade name)	FDA indication
Aztreonam solution (Cayston)	Improvement of respiratory symptoms in patients ≥6 yr of age with CF, FEV1 of >25% and <75%, and P. aeruginosa infection
Colistin dry powder (Colobreathe)	Not FDA approved; approved by the EMA for management of chronic pulmonary infections due to P. aeruginosa in patients ≥6 yr of age with CF
Tobramycin inhalation solution (Tobi)	Management of CF patients >6 yr of age with P. aeruginosa infection with FEV1 of >25% and <75% on a 28-day alternating on/off schedule
Tobramycin inhalation powder (Tobi Podhaler)	Management of CF patients >6 yr of age with P. aeruginosa infection with FEV1 of >25% and <80% on a 28-day alternating on/off schedule